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Abstract
Objective Lifetime cumulative number of menstrual cy-
cles is related to breast cancer risk. The aim of this study is
to investigate the relation between this index and serum sex
hormone levels in postmenopausal women.
Methods Cross-sectional study including 860 naturally
postmenopausal Dutch participants of the European Pro-
spective Investigation into Cancer and Nutrition. Lifetime
cumulative number of menstrual cycles was computed
using questionnaire data on ages at menarche and meno-
pause, number of pregnancies, breastfeeding, oral contra-
ceptive use (OC) and regularity pattern. Measurements of
hormones included estrone (E1), estradiol (E2), ando-
strenedione, testosterone, sex-hormone binding globulin
(SHBG) and dehydroepiandrostenedione sulfate (DHEAS).
The relation between the lifetime cumulative number of
menstrual cycles and hormone levels was assessed using
analysis of covariance. Relations between reproductive
characteristics and hormone levels were also studied.
Adjustments for characteristics at blood collection included
age, years since menopause, BMI, hormone replacement
therapy use, OC use, smoking habits, alcohol intake and
physical activity were done.
Results Lifetime cumulative number of cycles was
related with SHBG; participants in the lowest category had
higher SHBG levels. For the separate characteristics,
DHEAS and androstenedione increased signiﬁcantly with
increasing age at menarche, while androstenedione and
testosterone decreased with increasing age at menopause.
For the parity characteristics, SHBG levels increased
according to the number of live births.
Conclusions Lifetime cumulative number menstrual cy-
cles was related only to SHBG. Therefore, free levels of
estrogens or androgens may be related to this number of
menstrual cycles estimate, reﬂecting lifetime exposure to
ovarian hormones.
Keywords Reproductive Characteristics  Breast Cancer 
Sex Hormones  Steroids  Cumulative number of
menstrual cycles  Risk Factors
Introduction
Breast cancer is strongly related to various hormonal fac-
tors. We know that different hormones play a key role in
the pathogenesis of invasive breast cancer in both, pre-
menopausal and postmenopausal women [1–4], likely
representing a direct effect of circulating hormones [5–7].
The patterns of risk associated with reproductive history
suggest that a prolonged exposure to ovarian hormones
increases breast cancer occurrence [8]. It has been well
established that early age at menarche, late age at meno-
pause, null parity and late age at ﬁrst full term pregnancy
(FFTP) are important risk factors for breast cancer [9–11].
These characteristics may have long lasting effects on
hormone metabolism, although data regarding reproductive
characteristics and hormone levels are still inconclusive
[12–16]
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Breast Cancer Res Treat (2008) 108:101–112
DOI 10.1007/s10549-007-9574-zIn an effort to measure the lifetime exposure to endog-
enous hormones, the concept of the ‘‘lifetime cumulative
number of menstrual cycles’’ was introduced as an index
that could reﬂect total ovarian exposure [17, 18]. The
‘‘lifetime cumulative number of cycles’’ summarizes
information such as menarche, parity, menopause, regu-
larity pattern, breast feeding and oral contraceptive (OC)
use. In previous studies we, but also others, related the
cumulative numbers of menstrual cycles to breast cancer
risk [17, 18]. Ovarian function, and therefore, ‘‘lifetime
number of menstrual cycles’’ is deﬁned by age at meno-
pause, and age at menopause is related to postmenopausal
estrogen levels [19]; with this rationale we studied the
association between the ‘‘lifetime number of menstrual
cycles’’ and hormone levels after the menopause. The
hypothesis ﬁts in, where a common factor at hypothalamic
level may affect the speed by which oocytes are being
used, increasing postmenopausal gonoadothopin levels and
maybe, stimulating ovarian testosterone release from the
remaining theca cells, as well as non ovarian estrogens
from adrenal origin.
The aim of this study was to evaluate the relation be-
tween the ‘‘lifetime cumulative number of menstrual cy-
cles’’ and the reproductive characteristics that contribute to
this estimate on one side, and plasma concentrations of sex
hormones on the other side, in order to elucidate the
mechanism by which reproductive risk factors could
inﬂuence hormone-related cancers.
Study design and methods
The Prospect-EPIC study is one of the two Dutch cohorts
participating in the European Prospective Investigation into
Cancer and Nutrition; a multi-center prospective study
carried out in 23 centers from 10 European countries [20].
A detailed description of the study population and data
collection of the Prospect-EPIC study has been published
elsewhere[21].Brieﬂy,17,357 womenaged49–70,residing
in Utrecht and its surroundings were recruited through a re-
gional, population-based, breast cancer screening program
between 1993 and 1997. Base-line characteristics were col-
lected on the basis of two self-administered questionnaires
(regarding lifestyle and nutrition). The lifestyle question-
naire contains information on demographic characteristics,
family history, past and current morbidity, reproductive
history (gynecologic and obstetric), smoking habits, and
physical activity. In addition, anthropometricmeasurements
(height,weight,andwaistandhipcircumference)weretaken
as well as a 30 ml blood sample. Within 24 h, samples of
4 ml serum,9 ml citrateplasma, 2 ml white blood cells, and
2 ml red blood cells were fractionated into 0.5 ml aliquots
and stored at –196 C. Blood samples were successfully
drawn from 97.5% of the participants [21]. All women
signed a written informed consent and the study was ap-
proved by the Institutional Review Board of the University
Medical Center Utrecht.
Of all Prospect-EPIC participants a 10% random sample
(n = 1736) was taken and hormone measurements were
done. For the present study, participants who used hormone
replacement therapy (HRT) or OC in the previous twelve
months were excluded (n = 311), as well as those women
with history any cancer other than non-melanoma cancer
(n = 25). From the remaining 1,400 participants only those
who underwent natural menopause were eligible (n = 860)
because only in them we had reliable information about
ovarian activity not masked by the absence of menstrual
cycles due to hysterectomy. Natural menopause was de-
ﬁned as the complete cessation of menstrual bleeding for
12 months preceding enrollment due to natural causes
(according to self-report).
We computed the ‘‘lifetime cumulative number of
menstrual cycles’’ of the women in this study. For parous
women, the number of menstrual cycles before a FFTP was
also estimated as we previously described [17]. Brieﬂy, the
‘‘lifetime cumulative number of menstrual cycles’’ was
computed from age at ﬁrst menstrual period to age at
menopause. Ages at menarche, at menopause and at FFTP
were recorded as continuous variables. Age at regulariza-
tion of cycles was computed according to the time between
menarche and the establishment of regular periods
(immediately after menarche, after 1, 2, 3, 5, or 10 years,
after FFTP or never regular). The regularity pattern was
deﬁned categorically as 24, 26, 28, 30 and 32 day cycles,
or always irregular. Information about OC use included:
age at start, number of years of use and age at last use. Data
about number of and age at each pregnancy, stillbirth,
miscarriage and abortion, if any, were available, as well as
the number of weeks of breastfeeding for each pregnancy.
We took all the previously mentioned variables into
account when computing the ‘‘lifetime cumulative number
of menstrual cycles’’, considering that each pregnancy,
stillbirth, miscarriage or abortion, resulted in an absence of
cycles for a period of 36, 28 and 12 weeks respectively.
We assumed that lactation results in a 6-week absence of
cycles [22]. Menstrual cycles due to OC use were com-
puted as 28 days duration (see Appendix). Considering that
irregular cycles are a combination of long and short men-
strual periods, the number of irregular cycles was com-
puted according to each participant’s regularity pattern; the
total number of irregular years was recorded in order to
make further adjustments. The number of menstrual cycles
was impossible to compute in the participants who reported
to be always irregular or never having regular periods,
therefore we added the ‘‘irregular’’ category as such in the
analysis (See appendix).
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123Bounded levels of estrogens and androgens were mea-
sured, levels of estrone (E1), estradiol (E2), androstenedi-
one, testosterone, sex hormone binding globulin (SHBG)
and dehydroepiandrostenedione sulfate (DHEAS) were
measured in plasma using commercially available double-
antibody radioimmunoassay (RIA) kits (Diagnostic System
Laboratories Inc., Webster, TX, USA). The following kits
were used: E1: DSL-8700, E2: DSL-39100, androstenedi-
one: DSL-4200, TST: DSL-4100 SHBG: DSL-6300 and
DHEAS: DSL-2700. The intra-assay coefﬁcients of varia-
tion were 5.6%, 3.9%, 4.3%, 7.7%, 3.0% and 5.2%
respectively. The inter-assay coefﬁcients of variation were
11.1%, 4.1%, 6.3%, 8.1%, 4.0% and 5.3% respectively. All
hormone assays were performed by the laboratory of the
Hormones and Cancer group at the International Agency for
Research on Caner (IARC). Although technically SHBG is
not a hormone, for reasons of convenience it will be referred
as such. We calculated the free-androgen index (FAI)
dividing testosterone by SHBG and multiplying by 100, the
SHGB/E2 index was calculated dividing SHBG by E2.
Data analysis
Means with their standard deviation (SD) values, or fre-
quencies of baseline characteristics were calculated. Con-
centrations of all hormones were logarithmically
transformed to produce approximately normal distribu-
tions. To make the results easily interpretable, we trans-
formed the mean and its 95% conﬁdence interval (CI) back
to their original scale, resulting in geometric means and
95% CIs. Geometric mean levels and 95% CIs were cal-
culated for each hormone (SHBG, E1, E2, androstenedi-
one, testosterone, DHEAS), SHBG/estradiol index (SHBG/
E2) and free androgen index (FAI).
Using analysis of covariance models, geometric mean
hormone levels were calculated for the different categories
of cumulative number of menstrual cycles (lifetime and
before a FFTP). The same analysis was also used for cat-
egories of age at menarche, age at menopause, parity,
number of children and age of FFTP. In order to build the
adjusted model we classiﬁed confounders in three catego-
ries as follows: Group A contained characteristics clearly
related to hormone levels such as age, years since meno-
pause and body mass index (BMI); Group B contained
factors possibly related to hormone levels like OC and
HRT use, smoking habits, physical activity and alcohol
consumption; group C contained characteristics unlikely
related to hormone levels such as marital status, education
level and family history of breast cancer. We ﬁrst adjusted
for all confounders of type A, B, and C, then we built
models by deleting B and C types of characteristics,
without affecting validity but increasing precision. In the
ﬁnal model we included confounders in group A and B,
therefore we adjusted for age at intake as a continuous
variable, number of years from menopause to inclusion in
the study, BMI at examination, use of HRT ever (Y/N), use
of OC ever (Y/N), smoking habits, alcohol consumption
and physical activity. Information on current alcohol use
was obtained from the food frequency questionnaire, total
alcohol consumption in grams per day was calculated from
questions in the number of glasses of wine, beer, fortiﬁed
wines, and liquor/spirits per day, week, month or year. One
glass of any alcoholic beverage was assumed to contain
10g of alcohol. With the daily physical activity data from
the general questionnaire, the Voorrips score was calcu-
lated (and was entered in the model as a continuous vari-
able), this score has been developed and validated
especially for women in this age group [23]. For analysis of
the ‘‘lifetime cumulative number of menstrual cycles’’ and
the ‘‘number of cycles before a FFTP’’ variables, we also
adjusted for more than one year of irregular cycles (Y/N).
Given that age at menopause can be determined using age
at intake in combination of years since menopause; when
analyzing age at menopause, the covariate years since
menopause was not entered in the model.
To test the signiﬁcance of the models’ linearity, median
values in each category for every variable were computed
accordingly. Subsequently these values were included as a
continuous variable in a linear regression model to test for
linear trends. Because there is no clear natural hierarchy,
the ‘‘always irregular’’ category was not included when
testing for trend for the ‘‘lifetime number of menstrual
cycles’’ and the ‘‘number of menstrual cycles before a
FFTP’’ variables. Additional mutual adjustments for
reproductive characteristics did not show any difference in
the observed trends. The Statistical Package for Social
Sciences for WINDOWS, version 14.0 (Chicago, IL), was
used for all statistical analysis, and all tests were two sided.
Results
General and reproductive characteristics of the Prospect-
EPIC women that were included in this study are shown on
Table 1. On average, participants were 60.2 years old at
enrollment; had a BMI of 26.2 kg/m
2 and the majority of
them (69.4%) had at least low technical-secondary educa-
tion. 113 (13.1 %) were nulliparous, and for the parous, the
mean age for a FFTP was 25.5 years old. Mean age at
menarche and menopause were 13.6 and 49.6 years old
respectively, the time from menopause to inclusion, was on
average 10.6 years. In 786 participants (91.4%) the lifetime
cumulative number of cycles was calculated, as we had
incomplete data regarding reproductive history in 74 wo-
men. The median number of lifetime menstrual cycles was
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123451.3, corresponding to 34.7 years of menstrual activity if
considering an average of 13 cycles per year. From the
747 parous participants, 64 had incomplete data to compute
the number of menstrual cycles before a FFT, in the
remaining 683 participants (91.4%), the median number of
menstrual cycles before a FFTP was 146.7 (approximately
11.3 years of menstrual activity). These results are consis-
tent with the previous data on such estimates for a larger
sample of the Prospect-EPIC participants as we previously
published [17]. Table 2 shows the geometric mean hormone
levels for all participants with 95% CIs of SHBG, E1, E2,
androstenedione, testosterone, DHEAS, SHBG/E2 and FAI.
Table 3 shows the unadjusted geometric mean hormone
levels and 95% CI for each hormone according to some
general and reproductive characteristics. When testing for
trend participants in the lower quartile of ‘‘lifetime
cumulative of menstrual cycles’’ had higher levels of
SHBG, androstenedione, testosterone and DHEAS than the
participants with the highest quartile (P trend = 0.015,
0.003, 0.052 and 0.035 respectively), and lower levels of
SHBG/E2 (P trend = 0.031).
In table 4 adjusted geometric means for each hormone
according to the reproductive characteristics are shown.
Participants in the lowest quartile of cumulative number of
menstrual cycles tended to have higher SHBG (P
trend = 0.013) and lower SHBG/E2 (P trend = 0.050)
levels. Androstenedione and DHEAS levels increased with
increasing age at menarche (P trend = 0.027 and 0.022
respectively), a similar tendency was observed for E2, al-
though the P for trend did not reach statistical signiﬁcance
(P trend = .058). Women with more children, tended to
have higher SBHG levels (P trend = 0.030), number of
children was also related to lower SHBG/E2 (p
trend = 0.010) levels. No association was found between
number of cycles before a FFTP, parity, age at FFTP and
any of the hormones. Age at menopause related inversely
with androstenedione and testosterone; women with older
Table 1 General and reproductive characteristics of the study
participants (n = 860)
Mean (SD)
General characteristics
Age at enrollment 60.2 (5.5)
BMI 26.2 (4.2)
Waist Hip ratio 0.797 (0.59)
Length (cm) 163.7 (6.1)
Weight (Kg) 70.1 (11.9)
Educational level (%)
- Primary education 263 (30.6)
- Low technical, secondary 384 (44.6)
- High technical, secondary 98 (11.4)
- Academic 115 (13.4)
Ever married (%) 805 (93.6)
Cigarette smoking habits (%)
- Never smoked 402 (46.7)
- Past smoker 275 (32)
- Current smoker 183 (21.3)
Mother or sister with BC (%) 123 (14.3)
Reproduction characteristics
Age at menarche 13.6 (1.6)
Nulliparous (%) 113 (13.1)
Age at FFTP
a 25.46 (3.8)
Number live born children
a 2.9 (1.4)
Age at menopause 49.6 (4.0)
Years since menopause 10.6 (6.0)
Oral contraceptive use (%) 384 (44.6)
Years of OC use
b 6
HRT use (%) 66 (7.7)
Years of HRT use
c 1
Lifetime number of menstrual cycles
(n = 786) 165 (21.0)
£ 415 177 (22.5)
416–453 171 (21.8)
454–490 161 (20.5)
‡491 112 (14.2)
Always irregular
d
Number of menstrual cycles before
FFTP (n = 683)
£ 118 167 (25.5)
119–147 160 (23.4)
148–185 118 (17.3)
‡186 143 (20.9)
Always irregular
d 95 (13.9)
a Among parous women
b Median, Among OC users
c Median, Among HRT users
d Participants in the always irregular category, reported to be never
regular
Table 2 Geometric mean serum sex hormone and SHBG levels
Hormone Mean, (95% CI)
SHBG lg/ml 18.1 (17.2–19.2)
Estrone pg/ml 15.2 (14.48–16.0)
Estradiol pg/ml 8.5 (8.2–8.8)
Androstenedione ng/ml 0.47 (0.45–0.49)
Testosterone total ng/ml 0.26 (0.25–0.27)
DHEAS ng/ml 455.1 (432.9–478.4)
SHBG- Estradiol index (lg/pg) 0.47 (0.44–0.50)
Free androgen index
[(Testosterone /SHBG*100 (ng/lg*100)]
4.6 (4.4–5.0)
104 Breast Cancer Res Treat (2008) 108:101–112
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123age at menopause tend to have lower levels of such hor-
mones (p trend = 0.024 and 0.015 respectively).
Discussion
The results of the present study suggest that the ‘‘lifetime
cumulative number of cycles’’ is related to SHBG and that
some reproductive characteristics are also associated to
postmenopausal serum sex hormone levels. We noted sig-
niﬁcant associations after adjusting for important con-
founders, the ‘‘lifetime cumulative number of menstrual
cycles’’ related inversely with levels of SHBG and posi-
tively with SHBG/E2. Age at menarche directly relates to
both DHEAS and androstenedione. Number of children
had a signiﬁcant relation with levels of SHBG and SHBG/
E2 and age at menopause was indirectly associated to
androstenedione and testosterone.
Several studies have investigated the relation between
reproductive risk factors and endogenous sex hormone
levels in postmenopausal women, but with conﬂicting re-
sults [6, 13, 15, 24–27]. The patterns of risk associated with
reproductive history suggest that prolonged exposure to
ovarian hormones increases breast cancer occurrence [8,
28, 29]. The cumulative number of menstrual cycles has
been used as a proxy for ovarian activity, women in the
highest quartile of the ‘‘lifetime cumulative number of
menstrual cycles’’ estimate, have an increased breast can-
cer risk when compared with women in the lowest quartile
[17, 18]. A signiﬁcant inverse relation between number of
menstrual cycles and SHBG was observed in our study. It
has been previously described that SHBG decrease the
proportion of E2 that is able to leave the circulation and
enter the cells, and an inverse relation between concen-
tration of SHBG and breast cancer has been observed in
epidemiological studies [1, 10]. Our ﬁndings suggest
therefore, that postmenopausal free levels of estrogens or
androgens may be related to the ‘‘lifetime cumulative
number of menstrual cycles’’ reﬂecting lifetime exposure
to ovarian hormones.
Early age at menarche and late age at menopause have
long being recognized as risk factors for breast cancer. A 1-
year delay in the onset of menarche is associated with a 5%
reduction in risk for developing breast cancer in later life
[30]. We found that age at menarche has a direct relation
with serum levels of DHEAS and androstenedione mea-
sured after the menopause. Androgens have been associ-
ated with breast cancer risk, women with breast cancer tend
to have higher levels of DHEAS and androstenedione [2, 4,
31, 32]. It has been proposed that in postmenopausal wo-
men DHEAS might act as a moderate estrogen agonist,
through competitive binding of its metabolite 5-andro-
stene-3B,17B-diol [33]. It is also well known that the
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123peripheral conversion of adrenal androstenedione is the
principal source of E1 in postmenopausal women [34],
therefore we would expect an inverse association between
both DHEAS and androstenedione and age at menarche.
Madigan et al. showed, after adjusting for BMI and years
since menopause, that young age at menarche, was asso-
ciated with higher levels of androstenedione, but also of E1
and E2 [15]. Our results are in conﬂict with such ﬁndings,
however several studies have found no association between
age at menarche and SHBG, estrogens or androgens [14,
16, 35, 36].
Childbearing and a young age at FFTP protect against
breast cancer and additional pregnancies further reduce
the risk [7, 10, 37, 38]. We found that parous women tend
to have lower levels of E1, however this difference was
not statistically signiﬁcant (P = .072). Lamar et al. [14]
found that nulliparous women had higher testosterone
levels, a ﬁnding that could contribute to the increased risk
of breast cancer in nulliparous women. Our ﬁndings also
showed that the number of live births is directly related to
SHBG, and indirectly to SHBG/E2 and FAI (P for trend
for FAI did not reach statistical signiﬁcance, P = 0.064).
This observation is in conﬂict with the known association
between low SBGH levels and breast cancer risk, and the
protective effect that the number of pregnancies has on
breast cancer [28, 29, 38, 39]. It is important to mention
that a woman’s genetic and environmental proﬁle may
inﬂuence both, her ability to have children and her post-
menopausal sex hormone concentrations, making these
observations difﬁcult to interpret. It has been hypothe-
sized that the overall effect of parity is due to a protective
effect of a young age at FFTP [40], another proposed
mechanism is through lactation, as breastfeeding induces
ﬁnal differentiation of the terminal duct epithelium mak-
ing it relatively insensitive to hormonal stimulation [41,
42]. Despite these observations we found no relation be-
tween age at FFTP and any of the hormones. No relation
between parity, number of pregnancies or age at FFTP
and serum hormone levels was reported by several stud-
ies. [12, 14–16, 43, 44].
We observed an indirect association between age at
menopause and both, androstenedione and testosterone.
Several studies have failed in ﬁnding an association be-
tween age at menopause and sex hormones [12, 14, 16],
however a direct association with menopause and andro-
stenedione has been reported [15], as well as a relation
between age at menopause and E2 in a group of 173
postmenopausal overweight women [13].
To appreciate the ﬁndings of our study, some strengths
and limitations need to be mentioned. The main advantage
is our large sample size, to the best of our knowledge this is
the largest study assessing the relationship between
reproductive risk factors and serum sex hormone levels in
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123naturally menopausal women and the ﬁrst one evaluating
the relationship between sex hormones and an index that
can be used as a proxy of ovarian exposure. Another
advantage is that we attempted to adjust for all relevant
covariates, in order to obtain fully adjusted estimates. The
participants in this cross-sectional study originated from a
random sample of a large cohort, and blood samples where
drawn from 97.5% of the 17,357 participants, favoring the
generalization of our results. Given the prospective nature
of the Prospect-EPIC study, and because participants were
recruited through an existing population-based breast can-
cer screening program, we included only disease-free
participants at baseline blood collection.
A limitation of this study is that only a single blood
sample was assayed per participant, however it has been
shown that a single measure provides substantial infor-
mation in postmenopausal women for E1, E2 and SHBG
[45]. Serial measurements of serum hormones in post-
menopausal women suggest that a single measurement
can reliably categorize women, at least over the short
term. Intraclass correlation coefﬁcients of hormone mea-
surements in serum collected over a 3-year period were
reported to be between 0.68 and 0.78 for the estrogens,
0.66 and 0.88 for the androgens, and 0.92 for SHBG [46].
We did not have information regarding premenopausal
sex hormone concentrations in the participants of this
study; it remains unknown whether some underlying
hormonal proﬁle could have inﬂuenced both, reproductive
capabilities and postmenopausal sex hormone concentra-
tions. It is also possible that premenopausal hormone
levels are more related to reproductive factors than post-
menopausal levels, and that is as a proxy for premeno-
pausal levels that postmenopausal levels relate to
reproductive characteristics. We should consider that the
data used regarding reproductive characteristics are prone
to recall errors. However, it is unlikely that recall errors
are related to endogenous hormone levels themselves, if
any misclassiﬁcation occurred, it would have been non-
differential.
In summary, in this group of naturally postmenopausal
women, the ‘‘lifetime cumulative number menstrual cy-
cles’’ was related only to SHBG, suggesting that free levels
of estrogens or androgens may be related to this index,
reﬂecting lifetime exposure to ovarian hormones. Our
ﬁndings show that some reproductive characteristics are
related to postmenopausal serum sex hormone levels,
however we do not ﬁnd clear evidence to explain the
mechanism by which reproductive risk factors inﬂuence
hormone-related cancers in naturally postmenopausal wo-
men. It seems that reproductive and menstrual character-
istics do not affect postmenopausal breast cancer risk via a
long-term effect on sex hormone levels. The association of
reproductive risk factors and breast cancer could be a result
of prolonged exposure to ovarian hormones, and not only
the product of a direct, long-lasting effect of sex hormone
serum concentrations. Further research is needed in order
to unravel the biological mechanisms through which
reproductive characteristics relate to breast cancer risk.
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Appendix
This is a simple example of a woman with an age at
menarche of 12 years, one miscarriage at 23, an age at
FFTP of 25 and 2 children who she breastfeed 10 weeks
and 7 weeks. This participant also reported to have regular
periods since her menarche with cycles every 30 days, OC
use during 5 years starting at age 29, and having meno-
pause at age 51. Her number of menstrual cycles until her
FFTP is 147, and the number of menstrual cycles during
her lifetime is 452.8.
Number of cycles until FFTP: 25 years at
FFTP—12 years at menarche = 13 years. 13 years ·
52.178 weeks in one year = 678.314 weeks in 13 years
—(12 weeks miscarriage at 23)—(36 weeks ﬁrst preg-
nancy) = 630.31 weeks = 4412.198 days. 4412.198 days /
30 = 147.07 cycles (30 days duration).
Lifetime number of menstrual cycles: 51 years at men-
opause –12 years at menarche = 39 (–5 years OC
use = 34). 34 years · 52.178 weeks in one
year = 1774.071 weeks in 34 years—(12 weeks of mis-
carriage)—36 · 2 weeks of two pregnancies)—(17 weeks
total breastfeeding)—(6 · 2 weeks absence of cycles after
lactation) = 1661.071 weeks = 11627.5 days.
11627.5 days/30 = 387.58 cycles (30 days duration).
5 years of OC use · 365.25 = 1461 days in 5 years,
1826.25/28 = 65.22 cycles (28 days duration due to OC
use. 387.58 + 65.22 = 452.8 menstrual cycles during life-
time.
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